CN100363042C - Composition comprising biphenyldicarboxylate - Google Patents
Composition comprising biphenyldicarboxylate Download PDFInfo
- Publication number
- CN100363042C CN100363042C CNB2006101094798A CN200610109479A CN100363042C CN 100363042 C CN100363042 C CN 100363042C CN B2006101094798 A CNB2006101094798 A CN B2006101094798A CN 200610109479 A CN200610109479 A CN 200610109479A CN 100363042 C CN100363042 C CN 100363042C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- chinese medicine
- bifendate
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a synergic medicinal composition containing biphenyldicarboxylate and Chinese medicinal extracts, and its use in preparing medicament for the subsidiary treatment of hepatitis.
Description
Invention field
The present invention relates to the Pharmaceutical composition formed by bifendate and Chinese medicine extract, and the purposes of said composition in the medicine of preparation adjuvant treating hepatitis.
Background technology
Hepatitis has multiple sorting technique clinically, classifies as (1) nosetiology: viral hepatitis can be divided into five types is first, second, third, fourth, penta.(2) clinical classification can be divided into following a few type: 1. acute anicteric hepatitis, this is a modal type in the viral hepatitis, see with B-mode, third type, hepatitis D more, general this type of hepatitis clinical symptoms is less, and transaminase's elevated levels is lower, and Histological change is light, mortality rate is lower, but the course of disease can be delayed the long period, and " three is slow " characteristics are arranged, and morbidity is slow, recovery is slow, delay also slow (referring to the long meaning slowly); 2. acute icterohepatitis is less relatively compared with anicteric hepatitis, and the state of an illness is a self limiting often, and how good prognosis is, but minority can develop into hepatitis gravis; 3. chronic hepatitis: relevant experts in 1994 propose the name and the suggestion of chronic hepatitis again, with the cause of disease is the diagnosis name that chronic hepatitis is determined on the basis, simultaneously ordered grade scale, formulated standard by stages according to degree of hepatic fibrosis again according to the downright bad order of severity of hepatitis inflammation; 4. hepatitis gravis can be divided into acute heavy type, severe subacute and chronic heavy type again; 5. cholestatic hepatitis.
Wherein hepatitis B is caused by hepatitis B virus, serves as main a kind of infectious disease that also can cause multiple organ injury with the liver inflammatory lesion.China is the most popular country of hepatitis B, reaches more than 35% some local crowd infection rate, and be the most serious infectious disease of current harm people ' s health.According to investigations, China's hepatitis B patient is about 2,700 ten thousand, and annual New Development patient about 9,000,000.
The hepatitis B clinical manifestation is various, easily develops into chronic hepatitis and liver cirrhosis, and a few peoples finally develop into hepatocarcinoma.Hepatic fibrosis is the total pathological change of many chronic hepatopathy evolutions, and the damage of chronic, persistence is the prerequisite that hepatic fibrosis forms.Cause the factor of hepatic injury a lot,, hepatitis B, liver cirrhosis, take some drugs for a long time and can cause acute and chronic liver injury generally because of factors such as medicine, a large amount of ethanol, allergy cause acute liver damage.By reducing detrimental effect to liver function, can adjuvant treating hepatitis.
The medicine that is used for the treatment of the acute and chronic hepatic injury at present, commonly used have bifendate, a diammonium glycyrrhizinate etc.These chemicalses generally have certain side effect, and cause that therapeutic effect at a specified future date is poor, problem such as Strain produces after drug resistance phenomenon, the drug withdrawal relapse rate height.
The curative effect of Chinese medicine hepatitis B is proved by a large amount of clinical trials.Chinese medicine all can be brought into play curative effect preferably at aspects such as antiviral, adjusting immunity of organisms, protection hepatocyte.But Chinese medicine preparation ubiquity onset at present is slow, needs problems such as life-time service.Therefore, Western medicine and Chinese Medicine and Clavicular need be got up, i.e. synergism is played in Chinese medicine and western medicine combination, solves the problem that above-mentioned Western medicine and Chinese medicine exist in auxiliary treatment all kinds hepatitis separately, produces synergistic therapeutic effect simultaneously.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of bifendate and a kind of Chinese medicine extract, and wherein the Chinese medicine extract of said composition prepares according to the method for claim 2 among the Chinese patent CN1060067C, and is as follows:
With the weight ratio Semen phaseoli radiati: Bulbus Allii=1: 1 is a raw material, adds 10 times in water, decocts the medicine juice that made in 1 hour, drying under reduced pressure, extractum.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in preparation auxiliary treatment all kinds hepatitis medicament.
This Chinese medicine the water extracted immersing paste is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong transaminase lowering effect, i.e. function for protecting liver and reducing enzyme activity.
Edit with reference to Zhang Juntian, " modern pharmacology test method " (volume two), combined publication society of China Concord Medical Science University of Beijing Medical University, the 1397-1398 page or leaf, disclosed method in " first segment chmice acute chemical liver injury model ", set up the acute chemical liver injury model of mouse carbon tetrachloride, carry out the pharmacodynamics test of Pharmaceutical composition anti-liver injury of the present invention.
The test grouping:
1 normal control group: animal does not do any processing, and normal physiological saline is irritated stomach;
2 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: the water extracted immersing paste 0.86g/kg body weight as indicated above
3 bifendate groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight bifendate+the water extracted immersing paste 0.86g/kg body weight mentioned above is irritated stomach.
Following table has shown the influence of each group to Mouse Liver function leading indicator GOT, GPT.
| Group | Number of animals | GOT (active unit) | GPT (active unit) |
| The normal control group | 10 | 24.32±17.36 | 50.32±18.07 |
| Model control group | 10 | 254.85±77.21 | 308.63±59.78 |
| Pure Chinese drug-treated group | 10 | 188.27±68.71 | 235.71±55.71 |
| The bifendate group | 10 | 110.85±38.93 | 191.01±23.86 |
| The compositions group | 10 | 87.65±28.74 | 108.37±47.23 |
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, bifendate group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and bifendate group.Show that there are cooperative effect in bifendate and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio bifendate and Chinese medicine extract mentioned above at 1: 86.
Can produce the capsule that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio bifendate and Chinese medicine extract mentioned above at 1: 86.
Claims (2)
1. the Pharmaceutical composition of an anti-liver injury, it is made up of with weight ratio bifendate and Chinese medicine extract at 1: 86, and described Chinese medicine extract is by following method preparation: with the weight ratio Semen phaseoli radiati: Bulbus Allii=1: 1 is a raw material, add 10 times in water, decoct the medicine juice that made in 1 hour, drying under reduced pressure gets extractum.
The Pharmaceutical composition of anti-liver injury as claimed in claim 1 the preparation adjuvant treating hepatitis medicine in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101094798A CN100363042C (en) | 2006-08-17 | 2006-08-17 | Composition comprising biphenyldicarboxylate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101094798A CN100363042C (en) | 2006-08-17 | 2006-08-17 | Composition comprising biphenyldicarboxylate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1907422A CN1907422A (en) | 2007-02-07 |
| CN100363042C true CN100363042C (en) | 2008-01-23 |
Family
ID=37698759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101094798A Expired - Fee Related CN100363042C (en) | 2006-08-17 | 2006-08-17 | Composition comprising biphenyldicarboxylate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100363042C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1018242B (en) * | 1988-09-14 | 1992-09-16 | 法国钢铁冶金研究所 | Lateral wall for installation for continuous casting between movable walls, installation processing this wall and suitable process for continuous casting of thin metal products |
| CN1171942A (en) * | 1996-07-30 | 1998-02-04 | 侯唯动 | Drug for curing jaundice |
-
2006
- 2006-08-17 CN CNB2006101094798A patent/CN100363042C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1018242B (en) * | 1988-09-14 | 1992-09-16 | 法国钢铁冶金研究所 | Lateral wall for installation for continuous casting between movable walls, installation processing this wall and suitable process for continuous casting of thin metal products |
| CN1171942A (en) * | 1996-07-30 | 1998-02-04 | 侯唯动 | Drug for curing jaundice |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1907422A (en) | 2007-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100444857C (en) | Medicine for auxiliary treating hepatitis | |
| CN101810694B (en) | Traditional Chinese medicine and western medicine composition for adjunctive therapy of hepatitis | |
| CN101502551B (en) | Synergistic composition containing bifendate | |
| CN100367978C (en) | Synergistic medicinal composition | |
| CN100356962C (en) | Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate | |
| CN100356961C (en) | Synergistic medicinal composition for treating hepatitis | |
| CN100366282C (en) | Medicinal compositions comprising biphenyldicarboxylate | |
| CN100450498C (en) | Accessory medicinal composition for treating hepatitis | |
| CN100393337C (en) | Synergistic medicinal composition | |
| CN101837036B (en) | Synergetic medicinal composition | |
| CN100363042C (en) | Composition comprising biphenyldicarboxylate | |
| CN100363045C (en) | Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate for treating hepatitis accessorily | |
| CN100421690C (en) | Chinese-western medicine composition for treating hepatitis | |
| CN100353981C (en) | Medicine for auxiliary treating hepatitis | |
| CN101264181B (en) | Auxiliary treating hepatitis Chinese and Western medicines composition containing biphenyldicarboxylate and Chinese medicine extraction | |
| CN100363035C (en) | Cooperative medicinal composition comprising biphenyldicarboxylate and traditional Chinese medicine extract | |
| CN100363040C (en) | Medicinal compositions comprising biphenyldicarboxylate | |
| CN100356958C (en) | Synergistic medicinal composition for treating hepatitis | |
| CN101502572A (en) | Auxiliary Chinese and western medicinal composition for treating hepatitis | |
| CN100355446C (en) | Synergistic medicinal composition | |
| CN101797339B (en) | Synergistic medicinal composition containing oleanolic acid | |
| CN100421686C (en) | Chinese-western medicine composition for treating hepatitis | |
| CN100421692C (en) | Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate | |
| CN100569253C (en) | A kind of medicine of adjuvant treating hepatitis | |
| CN100353978C (en) | Synergistic medicinal composition containing tiopronin and Chinese medicine extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Xue Document name: Notification of Passing Examination on Formalities |
|
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Xue Document name: Notification to Pay the Fees |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Xue Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |